The estimated Net Worth of Melissa B, Epperly is at least $5.34 Million dollars as of 12 February 2024. Ms Epperly owns over 2,573 units of Zentalis Pharmaceuticals, Llc stock worth over $1,467,209 and over the last 5 years she sold ZNTL stock worth over $3,870,509.
Ms has made over 17 trades of the Zentalis Pharmaceuticals, Llc stock since 2020, according to the Form 4 filled with the SEC. Most recently she sold 2,573 units of ZNTL stock worth $29,435 on 12 February 2024.
The largest trade she's ever made was buying 20,000 units of Zentalis Pharmaceuticals, Llc stock on 7 April 2020 worth over $360,000. On average, Ms trades about 4,650 units every 52 days since 2020. As of 12 February 2024 she still owns at least 451,449 units of Zentalis Pharmaceuticals, Llc stock.
You can see the complete history of Ms Epperly stock trades at the bottom of the page.
Melissa B. Epperly M.B.A. is the CFO & Treasurer at Zentalis Pharmaceuticals, Llc.
Ms A is 43, she's been the CFO & Treasurer of Zentalis Pharmaceuticals, Llc since . There are 4 older and no younger executives at Zentalis Pharmaceuticals, Llc. The oldest executive at Zentalis Pharmaceuticals, Llc is Dr. Dimitris Voliotis M.D., 57, who is the Sr. VP of Clinical Devel..
Melissa's mailing address filed with the SEC is 800 WEST EL CAMINO REAL, SUITE 180, MOUNTAIN VIEW, CA, 94040.
Over the last 5 years, insiders at Zentalis Pharmaceuticals, Llc have traded over $106,453,887 worth of Zentalis Pharmaceuticals, Llc stock and bought 5,536,611 units worth $121,990,782 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management Company,... und Anthony Y Sun. On average, Zentalis Pharmaceuticals, Llc executives and independent directors trade stock every 11 days with the average trade being worth of $188,516. The most recent stock trade was executed by Cam Gallagher on 31 May 2024, trading 9,597 units of ZNTL stock currently worth $114,972.
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
Zentalis Pharmaceuticals, Llc executives and other stock owners filed with the SEC include: